AC Immune price target lowered to $12 from $16 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on AC Immune (ACIU) to $12 from $16 and keeps a Buy rating on the shares. The interim 26-week data from the ACI-7104.056 VacSYn Phase 2 trial showed that the vaccine continues to be safe, the analyst tells investors in a research note. The firm updated the stock’s discount rate to better reflect the current macro environment for Smid-cap biotech companies.